Finally, aside from CD8+ TILs, PD-L1 expression and TMIT, there are other biomarkers that may predict the efficacy of anti-PD1 immunotherapy, such as tumour mutational burden, lactate dehydrogenase concentration in serum and pro-inflammatory interferon gene signature [24]. Here, PDCD1 is linked to neoplasm.